NR1H4 and metabolic dysfunction-associated steatotic liver disease: In patients with non-alcoholic fatty liver disease (NAFLD) or in mouse models, treatment with FXR agonist obeticholic acid (OCA) produced a series of related liver effects, reducing triglycerides (TAGs) and inflammation, and alleviating steatohepatitis and liver fibrosis (37).